Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enpatoran mass balance, ADME, and absolute bioavailability study in healthy men
NL-OMON50534Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of enpatoran in systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE) and coronavirus pneumonia, sponsored by Merck KGaA. Primary endpoints: Rates and routes of excretion and mass balance, Total radioactivity pharmacokinetics in plasma and whole blood and 2 more. Started Nov 2021; status: completed.
02
Drugs
enpatoran
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)coronavirus pneumonia
Beyond the preview
Go deeper on NL-OMON50534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50534.